Your browser doesn't support javascript.
loading
Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer.
Yurgelun, Matthew B; Chittenden, Anu B; Morales-Oyarvide, Vicente; Rubinson, Douglas A; Dunne, Richard F; Kozak, Margaret M; Qian, Zhi Rong; Welch, Marisa W; Brais, Lauren K; Da Silva, Annacarolina; Bui, Justin L; Yuan, Chen; Li, Tingting; Li, Wanwan; Masuda, Atsuhiro; Gu, Mancang; Bullock, Andrea J; Chang, Daniel T; Clancy, Thomas E; Linehan, David C; Findeis-Hosey, Jennifer J; Doyle, Leona A; Thorner, Aaron R; Ducar, Matthew D; Wollison, Bruce M; Khalaf, Natalia; Perez, Kimberly; Syngal, Sapna; Aguirre, Andrew J; Hahn, William C; Meyerson, Matthew L; Fuchs, Charles S; Ogino, Shuji; Hornick, Jason L; Hezel, Aram F; Koong, Albert C; Nowak, Jonathan A; Wolpin, Brian M.
Afiliación
  • Yurgelun MB; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. matthew_yurgelun@dfci.harvard.edu.
  • Chittenden AB; Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA. matthew_yurgelun@dfci.harvard.edu.
  • Morales-Oyarvide V; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Rubinson DA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Dunne RF; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Kozak MM; Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA.
  • Qian ZR; Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
  • Welch MW; Department of Radiation Oncology, Stanford Cancer Institute, Stanford, CA, USA.
  • Brais LK; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Da Silva A; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Bui JL; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Yuan C; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Li T; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Li W; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Masuda A; Department of Radiation Oncology, Stanford Cancer Institute, Stanford, CA, USA.
  • Gu M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Bullock AJ; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Chang DT; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Clancy TE; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Linehan DC; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Findeis-Hosey JJ; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Doyle LA; Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
  • Thorner AR; Department of Radiation Oncology, Stanford Cancer Institute, Stanford, CA, USA.
  • Ducar MD; Department of Surgery, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, USA.
  • Wollison BM; Department of Surgery, University of Rochester Medical Center, Rochester, NY, USA.
  • Khalaf N; Department of Pathology, University of Rochester Medical Center, Rochester, NY, USA.
  • Perez K; Department of Pathology, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, USA.
  • Syngal S; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Aguirre AJ; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Hahn WC; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Meyerson ML; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Fuchs CS; Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA.
  • Ogino S; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Hornick JL; Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA.
  • Hezel AF; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Koong AC; Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA.
  • Nowak JA; Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA.
  • Wolpin BM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Genet Med ; 21(1): 213-223, 2019 01.
Article en En | MEDLINE | ID: mdl-29961768
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Adenocarcinoma / Predisposición Genética a la Enfermedad / Proteínas de Neoplasias Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Genet Med Asunto de la revista: GENETICA MEDICA Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Adenocarcinoma / Predisposición Genética a la Enfermedad / Proteínas de Neoplasias Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Genet Med Asunto de la revista: GENETICA MEDICA Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos